PMID- 36114412
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20221116
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Sep 16
TI  - Evaluation of lung toxicity with bevacizumab using the spontaneous reporting 
      database.
PG  - 15619
LID - 10.1038/s41598-022-19887-x [doi]
LID - 15619
AB  - This study was undertaken to determine the risk of bevacizumab-induced lung 
      toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug 
      Event Report database. We analysed data for the period between April 2004 and 
      March 2021. Data on lung toxicities were extracted, and relative risk of adverse 
      events (AEs) was estimated using the reporting odds ratio. We analysed 5,273,115 
      reports and identified 20,399 reports of AEs caused by bevacizumab. Of these, 
      1679 lung toxicities were reportedly associated with bevacizumab. Signals were 
      detected for nine lung toxicities. A histogram of times to onset showed 
      occurrence from 35 to 238 days, but some cases occurred even more than one year 
      after the start of administration. Approximately 20% of AEs were thromboembolic 
      events. Among these, pulmonary embolism was the most frequently reported and 
      fatal cases were also reported. The AEs showing the highest fatality rates were 
      pulmonary haemorrhage, pulmonary infarction, and pulmonary thrombosis. In 
      conclusion, we focused on lung toxicities caused by bevacizumab as post-marketing 
      AEs. Some cases could potentially result in serious outcomes, patients should be 
      monitored for signs of onset of AEs not only at the start of administration, but 
      also over a longer period of time.
CI  - (c) 2022. The Author(s).
FAU - Kanbayashi, Yuko
AU  - Kanbayashi Y
AD  - Department of Education and Research Center for Clinical Pharmacy, Faculty of 
      Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, 
      Takatsuki, Osaka, 569-1094, Japan. yuko.kambayashi@ompu.ac.jp.
FAU - Uchida, Mayako
AU  - Uchida M
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1, 
      Kodominamihokotate, Kyotanabe-shi, Kyoto, Japan.
FAU - Kashiwagi, Misui
AU  - Kashiwagi M
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1, 
      Kodominamihokotate, Kyotanabe-shi, Kyoto, Japan.
FAU - Akiba, Hitomi
AU  - Akiba H
AD  - Department of Education and Research Center for Pharmacy Practice, Faculty of 
      Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, 97-1, 
      Kodominamihokotate, Kyotanabe-shi, Kyoto, Japan.
FAU - Shimizu, Tadashi
AU  - Shimizu T
AD  - School of Pharmacy, Hyogo Medical University, 1-3-6 Minatojima, Kobe, Hyogo, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20220916
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Bevacizumab/adverse effects
MH  - Databases, Factual
MH  - *Drug-Related Side Effects and Adverse Reactions/epidemiology
MH  - Humans
MH  - Lung
PMC - PMC9481601
COIS- The authors declare no competing interests.
EDAT- 2022/09/17 06:00
MHDA- 2022/09/21 06:00
PMCR- 2022/09/16
CRDT- 2022/09/16 23:36
PHST- 2022/04/03 00:00 [received]
PHST- 2022/09/06 00:00 [accepted]
PHST- 2022/09/16 23:36 [entrez]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/09/16 00:00 [pmc-release]
AID - 10.1038/s41598-022-19887-x [pii]
AID - 19887 [pii]
AID - 10.1038/s41598-022-19887-x [doi]
PST - epublish
SO  - Sci Rep. 2022 Sep 16;12(1):15619. doi: 10.1038/s41598-022-19887-x.